
Join to view full profile
10 Lea Ave #760Nashville, TN 37210
Dr. Dilawari is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Asma Dilawari is medical director of oncology at Thyme Care a value based cancer care company based in Nashville. She completed her medical education at the University of Tennessee Health Science Center College of Medicine and pursued her residency in internal medicine at George Washington University. She underwent extensive fellowship training in hematology and medical oncology at NYU Grossman School of Medicine. Dr. Dilawari has held notable positions such as a clinical reviewer at the FDA, and an Assistant Professor at Georgetown University. She has contributed to several publications, particularly focusing on FDA approval summaries for cancer treatments in respected journals like the Journal of Clinical Oncology. Her work also includes experience in acupuncture, health disparities, and integrative medicine. Dr. Dilawari has received CMS Meaningful Use Stage 1 and 2 certifications across various platforms for her accomplishments in medical oncology.
Education & Training
NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2005 - 2008
NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2006 - 2007
NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2005 - 2006
George Washington UniversityResidency, Internal Medicine, 2001 - 2004
University of Tennessee Health Science Center College of MedicineClass of 2001
Certifications & Licensure
MI State Medical License 2025 - 2029
FL State Medical License 2025 - 2028
GA State Medical License 2026 - 2028
WA State Medical License 2025 - 2028
TN State Medical License 2025 - 2028
NY State Medical License 2005 - 2028
MS State Medical License 2025 - 2027
American Board of Internal Medicine Medical Oncology- Join now to see all
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification MEDSEEK Empower, SymphonyCare, LLC, 2014-2015, 2017
- CMS Meaningful Use Stage 1 Certification ARIA oncology information system (for Medical Oncology), Varian Medical Systems, 2014-2015, 2017
- CMS Meaningful Use Stage 2 Certification ARIA Oncology Information System (for Medical Oncology), Varian Medical Systems, 2014-2015, 2017
Publications & Presentations
PubMed
- 6 citationsUS Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor-Positive, Unresectable or Metastatic...Asma Dilawari, Hui Zhang, Mirat Shah, Xin Gao, Mallorie Fiero
Journal of Clinical Oncology. 2025-09-10 - 1 citationsCardiac Adverse Events in Patients Receiving Immune Checkpoint Inhibitors in the Adjuvant Setting: An FDA Pooled Analysis.Asma Dilawari, Mori J Krantz, Ilynn Bulatao, Hee-Koung Joeng, Marc Neilson
Annals of Noninvasive Electrocardiology. 2025-05-01 - 22 citationsUS Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locall...Asma Dilawari, James Buturla, Christy Osgood, Xin Gao, Wei Chen
Journal of Clinical Oncology. 2024-12-01
Press Mentions
Thyme Care Expands Cancer Survivorship Program to Provide Longitudinal SupportJune 4th, 2026
Thyme Care Triples Its Multidisciplinary Care Team with Increased Focus on Often-Overlooked Survivorship PopulationJune 1st, 2025
New Study Reveals Startling Results for Cancer Patients Who Opt for Natural RemediesJuly 19th, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:

























